Overall, while targeting EGFR-driven tumorigenesis is a potentially effective therapeutic strategy, the unmet need for inhibitors with greater specificity towards GBM-associated EGFR mutations limits their current clinical actionability in GBM patients, and they should be administered in combination with other therapeutic agents to combat GBM resistance. This evidence concerns the gene EGFR and glioblastoma.